ID
IMMU

Integral Derivatives’s Immunomedics Inc IMMU Stock Holding History

Integral Derivatives’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-15,382
Closed -$47K – 1177
2015
Q4 		$47K Buy
15,382
+1,100
+8% +$3.07K ﹤0.01% 1022
2015
Q3 		$25K Buy
+14,282
New +$36.5K ﹤0.01% 1052

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Integral Derivatives's IMMU Position: Q1 2016 in Review

Integral Derivatives sold out of Immunomedics Inc (IMMU) in Q1 2016, closing a stake of 15,382 shares — an estimated $47K sold.

Integral Derivatives first reported a position in IMMU in Q3 2015 and held it in 2 quarters. The position peaked at $47K in Q4 2015. 87 funds tracked by Wall St. Rank hold IMMU as of Q1 2016.

  • Integral Derivatives reported no remaining Immunomedics Inc position as of Q1 2016 after selling out during the quarter.
  • Integral Derivatives sold 15,382 Immunomedics Inc shares in Q1 2016, an estimated $47K.
  • Integral Derivatives first reported a position in Immunomedics Inc in Q3 2015 and held it in 2 quarters.
  • Integral Derivatives's Immunomedics Inc position peaked at $47K in Q4 2015.
  • 87 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2016.

Based on Integral Derivatives's 13F filing for Q1 2016, filed 12 Apr 2016.